Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.
astrocytoma
glioblastoma
modulated electro-hyperthermia
tumor treating fields
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
30
11
2022
revised:
25
01
2023
accepted:
29
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects. A meta-analysis of randomized and observational studies about mEHT and TTF was conducted. A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25-59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32-89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53-81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects.
METHODS
METHODS
A meta-analysis of randomized and observational studies about mEHT and TTF was conducted.
RESULTS
RESULTS
A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25-59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32-89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53-81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%,
CONCLUSIONS
CONCLUSIONS
Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.
Identifiants
pubmed: 36765840
pii: cancers15030880
doi: 10.3390/cancers15030880
pmc: PMC9913117
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1106-1113
pubmed: 31026557
Anticancer Res. 2020 Oct;40(10):5801-5806
pubmed: 32988908
Br J Cancer. 2021 Feb;124(4):697-709
pubmed: 33144698
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
J Neurooncol. 2019 Jan;141(2):467-473
pubmed: 30506499
Front Oncol. 2019 Nov 01;9:1012
pubmed: 31737558
J Neurooncol. 2021 May;153(1):153-160
pubmed: 33881725
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Neurooncol. 2018 Aug;139(1):177-184
pubmed: 29644485
Front Oncol. 2022 Apr 29;12:896246
pubmed: 35574391
BMC Med Phys. 2009 Jan 08;9:1
pubmed: 19133110
J Neurooncol. 2010 Jul;98(3):395-405
pubmed: 20033471
Front Neurol. 2022 Jun 16;13:900377
pubmed: 35785334
JAMA Oncol. 2022 Oct 1;8(10):1493-1501
pubmed: 36006639
Sci Rep. 2020 Jul 15;10(1):11622
pubmed: 32669604
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
World Neurosurg. 2022 Apr;160:e61-e79
pubmed: 34973444
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
pubmed: 15977639
Biomed Res Int. 2020 Nov 13;2020:8814878
pubmed: 33274226
BMJ Open. 2017 Nov 3;7(11):e017387
pubmed: 29102988
Front Oncol. 2020 Sep 04;10:1690
pubmed: 33014841
Front Oncol. 2020 Apr 21;10:411
pubmed: 32373508
Cancers (Basel). 2022 Jul 28;14(15):
pubmed: 35954334
Cell Death Discov. 2016 Jun 13;2:16039
pubmed: 27551529
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Neurooncol Pract. 2022 May 07;9(5):354-363
pubmed: 36134016
Front Oncol. 2021 Sep 27;11:671972
pubmed: 34692470
Front Oncol. 2021 Feb 05;10:574012
pubmed: 33614476
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Front Oncol. 2021 Jun 24;11:670809
pubmed: 34249709
Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13
pubmed: 25213869
J Neurooncol. 2020 Feb;146(3):399-406
pubmed: 32020470
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
Neurooncol Pract. 2021 Apr 20;8(4):426-440
pubmed: 34277021
Cancer Res. 2004 May 1;64(9):3288-95
pubmed: 15126372
In Vivo. 2006 Nov-Dec;20(6A):721-4
pubmed: 17203754
Front Oncol. 2019 Sep 26;9:963
pubmed: 31616641
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Cell Death Discov. 2018 Dec 5;4:113
pubmed: 30534421
Neurosurg Rev. 2021 Aug;44(4):1943-1955
pubmed: 33037945
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
Br J Cancer. 2015 Jul 14;113(2):232-41
pubmed: 26125449
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Front Neurol. 2019 Jan 31;10:42
pubmed: 30766509
Int J Mol Sci. 2020 Aug 29;21(17):
pubmed: 32872532
Int J Hyperthermia. 2018 Dec;34(8):1316-1328
pubmed: 29353516
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792
pubmed: 31828428
Semin Oncol. 2014 Oct;41 Suppl 6:S14-24
pubmed: 25213870
Int J Technol Assess Health Care. 2005 Winter;21(1):119-25
pubmed: 15736523
J Neurooncol. 2017 Dec;135(3):545-552
pubmed: 28849310
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Neurooncol. 2020 May;147(3):653-661
pubmed: 32206976
Semin Oncol. 2014 Oct;41 Suppl 6:S25-34
pubmed: 25213871
Cancer Med. 2014 Jun;3(3):592-602
pubmed: 24574359
Acta Neurochir (Wien). 2022 Aug;164(8):1985-1993
pubmed: 35397674
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Neurooncol Adv. 2020 Sep 15;2(1):vdaa121
pubmed: 33215088
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
Cancer Med. 2015 Mar;4(3):383-91
pubmed: 25620708
Neurooncol Adv. 2022 Jun 21;4(1):vdac096
pubmed: 35821680
Am J Epidemiol. 1986 Nov;124(5):719-23
pubmed: 3766505
JAMA Oncol. 2018 Apr 01;4(4):495-504
pubmed: 29392280
CNS Oncol. 2017 Jul;6(3):185-193
pubmed: 28399638
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2022 Feb 1;40(4):403-426
pubmed: 34898238
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7
pubmed: 17551011
Semin Oncol. 2014 Jun;41 Suppl 4:S1-14
pubmed: 24794308
Neoplasma. 2017;64(5):803-808
pubmed: 28592133
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Integr Cancer Ther. 2019 Jan-Dec;18:1534735418812691
pubmed: 30580645